Sulodexide inhibits retinal neovascularization in a mouse model of oxygen-induced retinopathy

BMB Reports

Volumn 47, Issue 11, 2014, Pages 637-642

  Jo, Hyoung ^a   Jung, Sang Hoon ^a   Kang, Jun ^b   Yim, Hye Bin ^b   Kang, Kui Dong ^b  

^a Korea Institute of Science and Technology   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Angiogenesis; MMP; Retinopathy; Sulodexide; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; FLUORESCEIN ISOTHIOCYANATE; GELATINASE A; GELATINASE B; GLYCOSAMINOGLYCAN; OXYGEN; SULODEXIDE; VASCULOTROPIN A;

ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; FEMALE; INSTITUTE FOR CANCER RESEARCH MOUSE; MALE; METABOLISM; MOUSE; PATHOLOGY; RETINA; RETINA NEOVASCULARIZATION; RETINAL DISEASES;

ANGIOGENESIS INHIBITORS; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; GLYCOSAMINOGLYCANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED ICR; OXYGEN; RETINA; RETINAL DISEASES; RETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84914814617     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2014.47.11.009     Document Type: Article

References (26)

1. Aiello, L. P., Pierce, E. A., Foley, E. D., Takagi, H., Chen, H., Riddle, L., Ferrara, N., King, G. L. and Smith, L. E. (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. U. S. A. 92, 10457-10461.
2. Kim, J, Kim, S. J., Chang, Y. S. and Park, W. S. (2014) Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity. Retina 34, 77-82.
3. Simpson, J. L., Melia, M., Yang, M. B., Buffenn, A. N., Chiang, M. F. and Lambert, S. R. (2012) Current role of cryotherapy in retinopathy of prematurity: a report by the American Academy of Ophthalmology. Ophthalmology 119, 873-877.
4. Condorelli, M., Chiariello, M., Dagianti, A., Penco, M., Dalla Volta, S., Pengo, V., Schivazappa, L., Mattioli, G., Mattioli, A. V. and Brusoni, B. (1994) IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J. Am. Coll. Cardiol. 23, 27-34.
5. Lasierra-Cirujeda, J., Coronel, P., Aza, M. and Gimeno, M. (2010) Use of sulodexide in patients with peripheral vascular disease. J. Blood Med. 1, 105-115.
6. Kristova, V., Liskova, S., Sotnikova, R., Vojtko, R. and Kurtansky, A. (2008) Sulodexide improves endothelial dysfunction in streptozotocin-induced diabetes in rats. Physiol. Res. 57, 491-494.
7. Corbu, C., Predoi, D. and Goicea, D. (1996) Sulodexide treatment in retinal vein obstructions. Oftalmologia 40, 393-397.
8. Weiss, R., Niecestro, R. and Raz, I. (2007) The role of sulodexide in the treatment of diabetic nephropathy. Drugs 67, 2681-2696.
9. Harenberg, J. (1998) Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med. Res. Rev. 18, 1-20.
10. Lauver, D. A. and Lucchesi, B. R. (2006) Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc. Drug Rev. 24, 214-226.
11. Pletinck, A., Van Landschoot, M., Steppan, S., Laukens, D., Passlick-Deetjen, J., Vanholder, R. and Van Biesen, W. (2012) Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion. Nephrol. Dial. Transplant. 27, 548-556.
12. Simonetti, O., Lucarini, G., Brancorsini, D., Nita, P., Bernardini, M. L., Biagini, G. and Offidani, A. (2002) Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer 95, 1963-1970.
13. Hollborn, M., Stathopoulos, C., Steffen, A., Wiedemann, P., Kohen, L. and Bringmann, A. (2007) Positive feedback regulation between MMP-9 and VEGF in human RPE cells. Invest. Ophthalmol. Vis. Sci. 48, 4360-4367.
14. Oshima, Y., Oshima, S., Nambu, H., Kachi, S., Hackett, S. F., Melia, M., Kaleko, M., Connelly, S., Esumi, N., Zack, D. J. and Campochiaro, P. A. (2004) Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization. J. Cell Physiol. 201, 393-400.
15. Yafai, Y., Iandiev, I., Wiedemann, P., Reichenbach, A. and Eichler, W. (2004) Retinal endothelial angiogenic activity: effects of hypoxia and glial (Muller) cells. Microcirculation 11, 577-586.
16. Pennock, S. and Kazlauskas, A. (2012) Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses. Mol. Cell Biol. 32, 1955-1966.
17. DeNiro, M., Al-Mohanna, F. H. and Al-Mohanna, F. A. (2011) Inhibition of reactive gliosis prevents neovascular growth in the mouse model of oxygen-induced retinopathy. PLoS One 6, e22244.
18. Gambaro, G., Kinalska, I., Oksa, A., Pont'uch, P., Hertlova, M., Olsovsky, J., Manitius, J., Fedele, D., Czekalski, S., Perusicova, J., Skrha, J., Taton, J., Grzeszczak, W. and Crepaldi, G. (2002) Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J. Am. Soc. Nephrol. 13, 1615-1625.
19. Broekhuizen, L. N., Lemkes, B. A., Mooij, H. L., Meuwese, M. C., Verberne, H., Holleman, F., Schlingemann, R. O., Nieuwdorp, M., Stroes, E. S. and Vink, H. (2010) Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 53, 2646-2655.
20. Packham, D. K., Wolfe, R., Reutens, A. T., Berl, T., Heerspink, H. L., Rohde, R., Ivory, S., Lewis, J., Raz, I., Wiegmann, T. B., Chan, J. C., de Zeeuw, D., Lewis, E. J. and Atkins, R. C. (2012) Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J. Am. Soc. Nephrol. 23, 123-130.
21. Watanabe, D., Suzuma, K., Suzuma, I., Ohashi, H., Ojima, T., Kurimoto, M., Murakami, T., Kimura, T. and Takagi, H. (2005) Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am. J. Ophthalmol. 139, 476-481.
22. Kim, N. H., Oh, J. H., Seo, J. A., Lee, K. W., Kim, S. G., Choi, K. M., Baik, S. H., Choi, D. S., Kang, Y. S., Han, S. Y., Han, K. H., Ji, Y. H. and Cha, D. R. (2005) Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int. 67, 167-177.
23. Smith, L. E., Wesolowski, E., McLellan, A., Kostyk, S. K., D'Amato, R., Sullivan, R. and D'Amore, P. A. (1994) Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 35, 101-111.
24. Li, S., Li, T., Luo, Y., Yu, H., Sun, Y., Zhou, H., Liang, X., Huang, J. and Tang, S. (2011) Retro-orbital injection of FITC-dextran is an effective and economical method for observing mouse retinal vessels. Mol. Vis. 17, 3566-3573.
25. Nanni, C., Pettinato, C., Ambrosini, V., Spinelli, A., Trespidi, S., Rubello, D., Al-Nahhas, A., Franchi, R., Alavi, A. and Fanti, S. (2007) Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies. Nucl. Med. Commun. 28, 547-553.
26. Connor, K. M., Krah, N. M., Dennison, R. J., Aderman, C. M., Chen, J., Guerin, K. I., Sapieha, P., Stahl, A., Willett, K. L. and Smith, L. E. (2009) Quantification of oxygen- induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat. Protoc. 4, 1565-1573.